Theseus Pharmaceuticals (THRX) IPO Opens 30% Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St climbs as oil slips; SpaceX spectrum deal weighs on telecoms
- Oil falls as Trump comments on Iran talks ease supply concerns
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- CoreWeave stock drops on dilution fears and debt concerns
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
- US consumer sentiment deteriorates further in October
- Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
- Anthropic launches cyber defense program for infrastructure and open-source
Theseus Pharmaceuticals Announces Pricing of Initial Public Offering
October 6, 2021 10:21 PM EDTCAMBRIDGE, Mass., Oct. 6, 2021 /PRNewswire/ --Â Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced the pricing of its initial public offering of 10,000,200 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being offered by Theseus. The gross proceeds to Theseus from the offering, before deducting underwriting discounts, commissions and other offering expenses payable by Theseus, are expected to be $160 million. In addition, Theseus has granted the underwriters a... More



